

Aleix Cases

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5728001/publications.pdf>

Version: 2024-02-01

155
papers

4,265
citations

126907

33
h-index

133252

59
g-index

174
all docs

174
docs citations

174
times ranked

4658
citing authors

#	ARTICLE	IF	CITATIONS
1	Medical Director Practice of Advising Increased Dietary Protein Intake in Hemodialysis Patients With Hyperphosphatemia: Associations With Mortality in the Dialysis Outcomes and Practice Patterns Study. , 2022, 32, 243-250.		3
2	Impacto pronóstico de la enfermedad renal crónica sobre el cierre percutáneo de la orejuela izquierda en la fibrilación auricular: una experiencia única. Nefrología, 2022, 42, 290-300.	0.4	2
3	Incidence of severe breakthrough SARS-CoV-2 infections in vaccinated kidney transplant and haemodialysis patients. Journal of Nephrology, 2022, 35, 769-778.	2.0	15
4	Trends in Mortality Due to Myocardial Infarction, Stroke, and Pulmonary Embolism in Patients Receiving Dialysis. JAMA Network Open, 2022, 5, e227624.	5.9	8
5	Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient. American Journal of Nephrology, 2022, 53, 333-342.	3.1	9
6	MO717: Prevalence and Management of Non-Valvular Atrial Fibrillation in Peritoneal Dialysis. Results of a Multicentric Survey. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
7	Prognostic impact of the presence of chronic kidney disease on percutaneous left atrial appendage closure for atrial fibrillation: A single center experience. Nefrología, 2022, , .	0.4	2
8	Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia. Cardiovascular Drugs and Therapy, 2021, 35, 521-532.	2.6	15
9	Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality. Kidney International Reports, 2021, 6, 214-218.	0.8	6
10	Beta-2 microglobulin and all-cause mortality in the era of high-flux hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study. CKJ: Clinical Kidney Journal, 2021, 14, 1436-1442.	2.9	12
11	Effect of comorbidities on survival in patients >80 years of age at onset of renal replacement therapy: data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2021, 36, 688-694.	0.7	4
12	Ferrotterapia en el manejo de la anemia en la enfermedad renal crónica no en diálisis: perspectiva del grupo de anemia de la S.E.N. Nefrología, 2021, 41, 123-136.	0.4	8
13	Iron replacement therapy in the management of anaemia in non-dialysis Chronic kidney disease patients: Perspective of the Spanish Nephrology Society Anaemia Group. Nefrología, 2021, 41, 123-136.	0.4	1
14	Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Frontiers in Medicine, 2021, 8, 642296.	2.6	91
15	Aplastic crisis secondary to parvovirus B19 primoinfección as an infrequent cause of anemia in an immunocompetent, non-dialysis chronic kidney disease patient. Clinical Nephrology, 2021, 95, 224-226.	0.7	1
16	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International, 2021, 99, 1280-1295.	5.2	103
17	Worldwide Early Impact of COVID-19 on Dialysis Patients and Staff and Lessons Learned: A DOPPS Roundtable Discussion. Kidney Medicine, 2021, 3, 619-634.	2.0	18
18	Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review. Frontiers in Medicine, 2021, 8, 654620.	2.6	1

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 Infection in a Spanish Cohort of CKD-5D Patients: Prevalence, Clinical Presentation, Outcomes, and De-Isolation Results. <i>Blood Purification</i> , 2021, 50, 531-538.	1.8	17
20	Concentración de hemoglobina reticulocitaria y ferroterapia en la enfermedad renal crónica: respuesta del grupo de Anemia de la Sociedad Española de Nefrología. <i>Nefrología</i> , 2021, , .	0.4	0
21	Changes in clinical indicators related to the transition from dialysis to kidney transplantation—data from the ERA-EDTA Registry. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 188-198.	2.9	1
22	Survival of patients treated with extended-hours haemodialysis in Europe: an analysis of the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 488-495.	0.7	15
23	Percutaneous left atrial appendage closure, a safe alternative to anticoagulation for patients with nonvalvular atrial fibrillation and end-stage renal disease on hemodialysis: A single center experience. <i>Artificial Organs</i> , 2020, 44, 513-521.	1.9	15
24	Upregulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 1713-1723.	3.6	18
25	P1455PRIORITIZATION BY MEDICAL DIRECTORS OF NUTRITIONAL PROTEIN VERSUS DIETARY PHOSPHORUS CONTROL IN HEMODIALYSIS PATIENTS: ASSOCIATION WITH MORTALITY IN THE DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (DOPPS). <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
26	Endothelial Damage, Inflammation and Immunity in Chronic Kidney Disease. <i>Toxins</i> , 2020, 12, 361.	3.4	43
27	Data from the ERA-EDTA Registry were examined for trends in excess mortality in European adults on kidney replacement therapy. <i>Kidney International</i> , 2020, 98, 999-1008.	5.2	27
28	FO043ENDOTHELIAL DAMAGE IN CHRONIC KIDNEY DISEASE IS MEDIATED THROUGH HISTONE DEACETYLASE UPREGULATION AND CAN BE PREVENTED BY DEFIBROTIDE. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
29	Vegetable-Based Diets for Chronic Kidney Disease? It Is Time to Reconsider. <i>Nutrients</i> , 2019, 11, 1263.	4.1	89
30	Sex Differences in Kidney Replacement Therapy Initiation and Maintenance. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1616-1625.	4.5	37
31	Changes in co-morbidity pattern in patients starting renal replacement therapy in Europe—data from the ERA-EDTA Registry. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1794-1804.	0.7	28
32	¿Son seguros y eficaces los antiagregantes plaquetarios en los pacientes con insuficiencia renal?. <i>CardiCore</i> , 2018, 53, 47-50.	0.0	1
33	Anemia of chronic kidney disease: Protocol of study, management and referral to Nephrology. <i>Nefrología</i> , 2018, 38, 8-12.	0.4	36
34	Anemia en la enfermedad renal crónica: protocolo de estudio, manejo y derivación a Nefrología. <i>Nefrología</i> , 2018, 38, 8-12.	0.4	30
35	Antioxidant and Anti-Inflammatory Strategies Based on the Potentiation of Glutathione Peroxidase Activity Prevent Endothelial Dysfunction in Chronic Kidney Disease. <i>Cellular Physiology and Biochemistry</i> , 2018, 51, 1287-1300.	1.6	43
36	Mortality due to bleeding, myocardial infarction and stroke in dialysis patients. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1953-1963.	3.8	13

#	ARTICLE	IF	CITATIONS
37	Sodium zirconium cyclosilicate: a new potassium binder for the treatment of hyperkalemia. <i>Drugs of Today</i> , 2018, 54, 601.	1.1	2
38	Prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease. <i>Drugs of the Future</i> , 2018, 43, 0023.	0.1	2
39	Insuficiencia cardíaca en la enfermedad renal y déficit de hierro: importancia de la ferroterapia. <i>Nefrología</i> , 2017, 37, 587-591.	0.4	4
40	Estimation of renal function by CKD-EPI versus MDRD in a cohort of HIV-infected patients: a cross-sectional analysis. <i>BMC Nephrology</i> , 2017, 18, 58.	1.8	17
41	Gut microbiota in chronic kidney disease. <i>Nefrología</i> , 2017, 37, 9-19.	0.4	51
42	Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA Study. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 135-142.	2.2	15
43	Microbiota intestinal en la enfermedad renal crónica. <i>Nefrología</i> , 2017, 37, 9-19.	0.4	92
44	Heart failure in patients with kidney disease and iron deficiency: The role of iron therapy. <i>Nefrología</i> , 2017, 37, 587-591.	0.4	2
45	Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function. <i>BMC Nephrology</i> , 2017, 18, 290.	1.8	10
46	TO021 DIRECT FACTOR Xa INHIBITOR APIXABAN PREVENTS ENDOTHELIAL ACTIVATION AND DAMAGE ASSOCIATED WITH CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, iii87-iii87.	0.7	1
47	Opinión sobre el empleo de estatinas y su efecto diabético: coincidencias y diferencias entre los médicos de atención primaria y otras especialidades (Estudio DIANA). <i>Medicina General Y De Familia</i> , 2017, 6, 148-154.	0.0	2
48	Anemia en la enfermedad renal crónica: protocolo de estudio, abordaje y derivación a Nefrología. <i>Medicina General Y De Familia</i> , 2017, 6, 204-208.	0.0	0
49	SP620 ANTIOXIDANT AND ANTIINFLAMMATORY STRATEGIES TO PREVENT ENDOTHELIAL DYSFUNCTION IN CHRONIC KIDNEY DISEASE: THE ROLE OF N-ACETYL CYSTEINE. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i302-i302.	0.7	0
50	Delphi consensus on the diagnosis and management of dyslipidaemia in chronic kidney disease patients: A post hoc analysis of the DIANA study. <i>Nefrología</i> , 2016, 36, 679-686.	0.4	0
51	Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: the NEFRONA study. <i>Nephrology Dialysis Transplantation</i> , 2016, 32, gfw039.	0.7	28
52	Consenso Delphi sobre el diagnóstico y manejo de la dislipidemia en pacientes con enfermedad renal crónica: análisis post-hoc del estudio DIANA. <i>Nefrología</i> , 2016, 36, 679-686.	0.4	2
53	Abstract 357: Antioxidant and Anti-inflammatory Strategies Prevent Endothelial Dysfunction in Chronic Kidney Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, .	2.4	0
54	FO020 ENDOTHELIAL DYSFUNCTION IN UREMIA: EFFECT OF FLAVONOIDS AND ANTIOXIDANTS. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii11-iii11.	0.7	0

#	ARTICLE	IF	CITATIONS
55	SaO ₀₃₆ UREMIC MEDIUM INDUCES CHANGES IN THE EXPRESSION OF GENES RELATED TO INFLAMMATION AND ATHEROTHROMBOSIS. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii38-iii39.	0.7	0
56	The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 791-799.	4.5	75
57	Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study1. <i>Nefrologia</i> , 2015, 35, 179-188.	0.4	3
58	<sc>TLR</sc>4 and <sc>NALP</sc>3 inflammasome in the development of endothelial dysfunction in uraemia. <i>European Journal of Clinical Investigation</i> , 2015, 45, 160-169.	3.4	58
59	Efficacy of a Simple Dosage Scheme to Convert From Shorter-acting Erythropoiesis-stimulating Agent to Continuous Erythropoietin Receptor Activator in Kidney Transplantation Patients. <i>Transplantation Proceedings</i> , 2015, 47, 73-75.	0.6	2
60	Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1176-1185.	0.7	85
61	Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis. <i>Circulation</i> , 2015, 132, 27-39.	1.6	259
62	Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study1. <i>Nefrologia</i> , 2015, 35, 179-188.	0.4	6
63	Carotid Atherosclerotic Disease Predicts Cardiovascular Events in Hemodialysis Patients: A Prospective Study. <i>PLoS ONE</i> , 2015, 10, e0127344.	2.5	13
64	C.E.R.A. administered once monthly corrects and maintains stable hemoglobin levels in chronic kidney disease patients not on dialysis: the observational study MICENAS II. <i>Nefrologia</i> , 2015, 35, 80-6.	0.4	1
65	Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study. <i>International Urology and Nephrology</i> , 2014, 46, 1983-1995.	1.4	2
66	Prevalence of anaemia and its clinical management in patients with stages 3-5 chronic kidney disease not on dialysis in Catalonia: MICENAS I study. <i>Nefrologia</i> , 2014, 34, 189-98.	0.4	27
67	Impact of the 5008 monitor software update on total convective volume. <i>Nefrologia</i> , 2014, 34, 599-604.	0.4	16
68	Sensitivity of Blood Volume Monitoring for Fluid Status Assessment in Hemodialysis Patients. <i>Blood Purification</i> , 2013, 35, 202-208.	1.8	268
69	Evolution of the incidence of chronic kidney disease Stage 5 requiring renal replacement therapy in the diabetic population of Catalonia. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1191-1198.	0.7	14
70	Practical utility of thermodilution versus doppler ultrasound to measure hemodialysis blood access flow. <i>Nefrologia</i> , 2013, 33, 325-32.	0.4	6
71	Nocturnal, every-other-day, online haemodiafiltration: an effective therapeutic alternative. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1619-1631.	0.7	47
72	NF κ B in the Development of Endothelial Activation and Damage in Uremia: An In Vitro Approach. <i>PLoS ONE</i> , 2012, 7, e43374.	2.5	35

#	ARTICLE	IF	CITATIONS
73	Successful treatment of calcific uraemic arteriopathy with bisphosphonates. <i>Nefrologia</i> , 2012, 32, 329-34.	0.4	38
74	Dialysate calcium individualisation: a pending issue. <i>Nefrologia</i> , 2012, 32, 579-86.	0.4	8
75	Level of dependence in patients on haemodialysis in Catalonia and evolution of mortality rates. <i>Nefrologia</i> , 2012, 32, 613-21.	0.4	4
76	Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study. <i>BMC Nephrology</i> , 2011, 12, 53.	1.8	76
77	What Infusion Flow Should Be Used for Mid-Dilution Hemodiafiltration?. <i>Blood Purification</i> , 2010, 30, 25-33.	1.8	9
78	Prevalence of Chronic Kidney Disease in Patients With or at a High Risk of Cardiovascular Disease. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 225-228.	0.6	8
79	Prevalencia de insuficiencia renal cr�nica en pacientes de alto riesgo o con enfermedad cardiovascular. <i>Revista Espanola De Cardiologia</i> , 2010, 63, 225-228.	1.2	15
80	Respuesta. <i>Revista Espanola De Cardiologia</i> , 2010, 63, 1001.	1.2	0
81	Mid-Dilution Hemodiafiltration: A Comparison with Pre- and Postdilution Modes Using the Same Polyphenylene Membrane. <i>Blood Purification</i> , 2009, 28, 268-274.	1.8	25
82	Haemodialysis through a cellulose membrane induces dephosphorylation of CD11b and promotes leukocyte adhesion to endothelial cells. <i>Clinical and Investigative Medicine</i> , 2009, 32, 48.	0.6	2
83	Differential Expression of Proteins From Cultured Endothelial Cells Exposed to Uremic Versus Normal Serum. <i>American Journal of Kidney Diseases</i> , 2008, 51, 603-612.	1.9	30
84	Influence of the Ionic Dialysate Monitor on Kt Measurement in Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2008, 52, 85-92.	1.9	28
85	Prevalence and Clinical Characteristics of HIV Type 1-Infected Patients Receiving Dialysis in Spain: Results of a Spanish Survey in 2006: GESIDA 48/05 Study. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1229-1235.	1.1	29
86	Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study. <i>Kidney International</i> , 2008, 74, S82-S87.	5.2	21
87	Polymicrobial Peritonitis in a Patient with Mixed Cryoglobulinemia. <i>Peritoneal Dialysis International</i> , 2008, 28, 99-100.	2.3	0
88	Chronic hypotension in hemodialysis patients: role of functional vascular changes and vasodilator agents. <i>Clinical Nephrology</i> , 2008, 69, 114-120.	0.7	11
89	Effect of Two Different Dialysis Membranes on Leukocyte Adhesion and Aggregation. <i>Nephron Clinical Practice</i> , 2007, 106, c1-c8.	2.3	7
90	Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 459-465.	0.7	32

#	ARTICLE	IF	CITATIONS
91	Dyslipidemia and the progression of renal disease in chronic renal failure patients. <i>Kidney International</i> , 2005, 68, S87-S93.	5.2	146
92	Improvement of renal function in azotaemic hypertensive patients after surgical revascularization. <i>British Journal of Surgery</i> , 2005, 75, 578-580.	0.3	15
93	A Proteomic Approach to the Characterization of the Endothelial Dysfunction in Uremia.. <i>Blood</i> , 2005, 106, 3955-3955.	1.4	2
94	Uremic platelet dysfunction: past and present. <i>Psychophysiology</i> , 2005, 4, 359-67.	1.1	62
95	Biocompatibility of Cellulosic and Synthetic Membranes Assessed by Leukocyte Activation. <i>American Journal of Nephrology</i> , 2004, 24, 235-241.	3.1	24
96	The effects of smoking and its cessation on 8-epi-PGF ₂ α and transforming growth factor-beta 1 in Type 1 diabetes mellitus. <i>Diabetic Medicine</i> , 2004, 21, 285-289.	2.3	19
97	Cigarette smoke concentrate increases 8-epi-PGF ₂ α; and TGFβ ₁ secretion in rat mesangial cells. <i>Life Sciences</i> , 2004, 75, 611-621.	4.3	26
98	Update in nephrology: Highlights from the 36th Annual Meeting of the ASN. <i>Drugs of Today</i> , 2004, 40, 81.	2.4	1
99	Interactions Between Vasoconstrictors and Vasodilators in Regulating Hemodynamics of Distinct Vascular Beds. <i>Hypertension</i> , 2003, 42, 831-836.	2.7	31
100	Uraemic medium accelerates proliferation but does not induce apoptosis of endothelial cells in culture. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1079-1085.	0.7	26
101	Darbepoetin alfa: A novel erythropoiesis-stimulating protein. <i>Drugs of Today</i> , 2003, 39, 477.	2.4	19
102	Erythropoietin Triggers a Signaling Pathway in Endothelial Cells and Increases the Thrombogenicity of their Extracellular Matrices In Vitro. <i>Thrombosis and Haemostasis</i> , 2002, 88, 678-685.	3.4	84
103	Morbimortalidad cardiovascular en la diabetes mellitus tipo 2. <i>Hipertension Y Riesgo Vascular</i> , 2002, 19, 193-196.	0.6	0
104	Nonconvulsive status epilepticus in dialysis patients. <i>American Journal of Kidney Diseases</i> , 2002, 39, 440.	1.9	7
105	Chronic hypotension in the dialysis patient. <i>Journal of Nephrology</i> , 2002, 15, 331-5.	2.0	20
106	Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. <i>Thrombosis and Haemostasis</i> , 2002, 88, 678-85.	3.4	30
107	Uremic medium causes expression, redistribution and shedding of adhesion molecules in cultured endothelial cells. <i>Haematologica</i> , 2002, 87, 1053-61.	3.5	43
108	Hipermineralocorticismo exógeno como causa de descompensación de una hipertensión esencial previamente controlada. <i>Hipertension Y Riesgo Vascular</i> , 2001, 18, 440-443.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Mecanismos de desarrollo del daño vascular en pacientes en diálisis. Hipertension Y Riesgo Vascular, 2001, 18, 374-382.	0.6	0
110	Uremic Medium Disturbs the Hemostatic Balance of Cultured Human Endothelial Cells. Thrombosis and Haemostasis, 2001, 86, 1099-1105.	3.4	31
111	Hemodynamic and renal effects of acute and progressive nitric oxide synthesis inhibition in anesthetized dogs. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2001, 280, R143-R148.	1.8	12
112	Effect of angiotensin II receptor blockade on renal disease progression in patients with non-diabetic chronic renal failure. Nephrology Dialysis Transplantation, 2001, 16, 82-84.	0.7	16
113	Abnormal platelet cytoskeletal assembly in hemodialyzed patients results in deficient tyrosine phosphorylation signaling. Kidney International, 2000, 57, 1905-1914.	5.2	27
114	Increased plasma adrenomedullin levels in hemodialysis patients with sustained hypotension. Kidney International, 2000, 57, 664-670.	5.2	40
115	β ₂ -adrenergic receptor density and function in left ventricular hypertrophy in young essential hypertensives. Journal of Human Hypertension, 2000, 14, 17-21.	2.2	9
116	Papel de la adrenomedulina en el control de la presión arterial y la homeostasis del líquido extracelular. Hipertension Y Riesgo Vascular, 2000, 17, 317-324.	0.6	0
117	Novel Erythropoiesis Stimulating Protein. Drugs of the Future, 2000, 25, 246.	0.1	3
118	Doxazosin in a gastrointestinal therapeutic system formulation. Drugs of Today, 2000, 36, 679.	1.1	7
119	Recombinant human erythropoietin treatment in chronic renal failure: Effects on hemostasis and vasculature. Drugs of Today, 2000, 36, 541.	1.1	4
120	Erythropoietin Improves Signaling through Tyrosine Phosphorylation in Platelets from Uremic Patients. Thrombosis and Haemostasis, 1999, 82, 1312-1317.	3.4	43
121	Smoking increases serum levels of transforming growth factor-beta in diabetic patients. Diabetes Care, 1999, 22, 1915-1916.	8.6	28
122	Lamifiban. Drugs of the Future, 1999, 24, 261.	0.1	3
123	Clinical pharmacology of nebivolol. Drugs of Today, 1999, 35, 685.	2.4	4
124	Effect of recombinant human erythropoietin treatment on circulating reticulated platelets in uremic patients: Association with early improvement in platelet function. , 1998, 59, 105-109.		33
125	Renal Failure in Multiple Myeloma. Archives of Internal Medicine, 1998, 158, 1889.	3.8	328
126	Platelet-Leukocyte Activation during Hemodialysis Detected with a Monoclonal Antibody to Leukocyte Integrin CD11b. Nephron, 1998, 80, 197-203.	1.8	17

#	ARTICLE	IF	CITATIONS
127	Advances in hypertension management: Update 1998. <i>Drugs of Today</i> , 1998, 34, 989.	2.4	0
128	Vasoactive hormones in uraemic patients with chronic hypotension. <i>Nephrology Dialysis Transplantation</i> , 1997, 12, 321-324.	0.7	12
129	Autonomic nervous system and adrenergic receptors in chronic hypotensive haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 1997, 12, 939-944.	0.7	28
130	New Insights Into the Pathophysiology of Renovascular Hypertension. <i>Mayo Clinic Proceedings</i> , 1997, 72, 251-260.	3.0	35
131	In Vivo Evaluation of Platelet Activation by Different Cellulosic Membranes. <i>Artificial Organs</i> , 1997, 21, 330-334.	1.9	15
132	Msp1 identifies a biallelic polymorphism in the promoter region of the β_2 -adrenoceptor gene. <i>Clinical Genetics</i> , 1997, 51, 129-130.	2.0	69
133	Correspondence. <i>American Journal of Hypertension</i> , 1996, 9, 708-709.	2.0	0
134	Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. <i>British Journal of Haematology</i> , 1995, 91, 854-859.	2.5	113
135	Reticulated platelets in uremic patients: Effect of hemodialysis and continuous ambulatory peritoneal dialysis. <i>American Journal of Hematology</i> , 1995, 50, 161-166.	4.1	28
136	Uraemic medium causes endothelial cell dysfunction characterized by an alteration of the properties of its subendothelial matrix. <i>Nephrology Dialysis Transplantation</i> , 1995, 10, 2199-2204.	0.7	35
137	Reversible Decrease of Surface β_2 -Adrenoceptor Number and Response in Lymphocytes of Patients with Pheochromocytoma. <i>Clinical and Experimental Hypertension</i> , 1995, 17, 537-549.	1.3	15
138	Effect of antihypertensive treatment on the increased β_2 -adrenoceptor density in patients with essential hypertension. <i>American Journal of Hypertension</i> , 1995, 8, 487-493.	2.0	9
139	Minimal-Change Glomerulopathy and Carcinoma. <i>American Journal of Nephrology</i> , 1993, 13, 69-72.	3.1	21
140	Intracellular calcium mobilization and activation of the Na^+/H^+ exchanger in platelets. <i>Biochemical Journal</i> , 1993, 290, 617-622.	3.7	28
141			

#	ARTICLE	IF	CITATIONS
145	Lymphocyte surface beta2-adrenoceptors in essential hypertension. <i>Journal of Hypertension</i> , 1991, 9, S100.	0.5	0
146	Tumor Markers in Chronic Renal Failure and Hemodialysis Patients. <i>Nephron</i> , 1991, 57, 183-186.	1.8	66
147	Lymphocyte surface beta2-adrenoceptors in essential hypertension. <i>Journal of Hypertension</i> , 1991, 9, S100.	0.5	2
148	Ocular and Auditory Toxicity in Hemodialyzed Patients Receiving Desferrioxamine. <i>Nephron</i> , 1990, 56, 19-23.	1.8	32
149	Lymphocyte β ² -Adrenergic Receptors in Essential Hypertension: Studies in Basal Conditions and After Dynamic Exercise. <i>Clinical and Experimental Hypertension</i> , 1989, 11, 303-309.	0.3	2
150	Treatment of Hyperkalaemia in Renal Failure: Salbutamol v. Insulin. <i>Nephrology Dialysis Transplantation</i> , 1989, 4, 228-232.	0.7	84
151	Reversal of Renal Failure after Revascularization in Atheromatous Renovascular Disease. <i>American Journal of Nephrology</i> , 1988, 8, 479-482.	3.1	5
152	Visceral Involvement of Dialysis Amyloidosis. <i>American Journal of Nephrology</i> , 1987, 7, 390-393.	3.1	64
153	A Possible Pathogenic Mechanism for Rhabdomyolysis Associated with Multiple Myeloma. <i>Acta Haematologica</i> , 1987, 77, 231-233.	1.4	8
154	NIFEDIPINE-INDUCED PAROTITIS. <i>Lancet</i> , The, 1986, 328, 467.	13.7	10
155	Rhabdomyolysis Associated With Pleural Tuberculosis. <i>Archives of Internal Medicine</i> , 1986, 146, 2411.	3.8	3